AstraZeneca

The precision medicine market is projected to grow by USD 66.2 billion from 2024-2028, driven by chronic disease prevalence and AI/ML integration, despite data privacy challenges.

Pharmaceutical and biotech companies often change names to reflect mission and focus. Notable changes include J&J renaming Janssen to Johnson & Johnson Innovative Medicine, BeiGene becoming BeOne Medicines, Vaccitech rebranding as Barinthus Biotherapeutics, Cullinan Oncology shifting to Cullinan Therapeutics, and Eliem Therapeutics renaming to Climb Bio.

FDA grants Merck's sacituzumab tirumotecan (sac-TMT) breakthrough therapy designation for advanced non-squamous NSCLC with EGFR mutations, post-chemotherapy progression. This marks the first BTD for sac-TMT, an ADC developed with Kelun-Biotech, with Merck holding global marketing rights except in Greater China.

DelveInsight's report on the Respiratory Syncytial Virus (RSV) market forecasts trends and epidemiology in the U.S., EU4, UK, and Japan until 2034. Key companies include Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others. Promising therapies in development include Nirsevimab, RSVpreF Vaccine, and others. The market is expected to grow due to increasing incident cases and upcoming therapies, despite current treatment limitations.

Novo Nordisk's CagriSema, combining semaglutide with cagrilintide, could be a breakthrough in obesity treatment. Analysts highlight amylin's role in satiety and hedonic eating, potentially improving weight reduction quality. Phase II results showed a 15.6% weight drop with CagriSema, and Phase III trials are ongoing. Competitors like Lilly and Zealand Pharma also advance amylin-based therapies, with promising early results.

Respiratory syncytial virus (RSV) market report by DelveInsight covers epidemiology, market forecast, and key companies like Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others. Promising therapies include Nirsevimab, RSVpreF Vaccine, RSVpreF3 Vaccine, MVA-BN RSV Vaccine, Ad26.RSV.pre F Vaccine, mRNA-1345 Vaccine, NJ-53718678, Clesrovimab, EDP-938, MEDI8897, GS-5806, RV521, ALN-RSV01, and others.

Sarepta Therapeutics, known for its focus on Duchenne muscular dystrophy, made a $500 million upfront deal with Arrowhead Pharmaceuticals, investing $325 million and up to $10 billion in milestones. The deal aims to diversify Sarepta's pipeline with RNA drugs and expand its portfolio into new disease areas. Despite Elevidys failing a confirmatory trial, Sarepta secured full FDA approval and a label expansion, generating $181 million in Q3. The deal reflects Sarepta's ability to secure regulatory success and diversify its portfolio, potentially offering new options for patients with rare diseases.

DelveInsight's report highlights a robust lupus nephritis pipeline with 30+ companies developing 35+ therapies, including key players like AstraZeneca and Novartis. Promising therapies like Anifrolumab and Ianalumab are in various clinical phases, with recent updates from companies like Adicet Bio and Kyverna Therapeutics. The report provides comprehensive insights into the pipeline, therapeutic assessments, and market dynamics.

Lung diseases like asthma, COPD, and lung cancer profoundly impact millions, with interconnected conditions exacerbating symptoms and outcomes. AstraZeneca is committed to addressing these challenges through innovative science, early detection, and equitable access to care, aiming to transform lung health globally.

T.C. has consulted/advised/spoken for ASCO Post, AstraZeneca, Bio Ascend, Bristol Myers Squibb, Clinical Care Options, Daiichi Sankyo, Genentech, IDEOlogy Health, Medical Educator Consortium, Medscape, Merck, OncLive, oNKo-innate, PEAK Medicals, PeerView, Pfizer, Physicians’ Education Resource, RAPT Therapeutics, Regeneron, Targeted Oncology. W.N.W.Jr. has consulted/advised/spoken for Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, Genentech/Roche, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Sanofi-Aventis, Takeda, United Medical.